U.S. Markets
AbbVie (ABBV) announces the submission of a BLA for etentamig, following the positive phase 3 CERVINO study
ORIGINAL · NewsquawkAbbVie (ABBV) announces the submission of a BLA for etentamig, following the positive phase 3 CERVINO study
StockNow breaking-news AI analysis
The headline reports a BLA submission announcement. Earlier CERVINO results reported improved response rate and progression-free survival, with safety findings and overall-survival boundary qualifications.
Related stocks
1 stocks
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.